By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Beta-blocker > Nebivolol

Nebivolol

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
4 min read|708 words

Nebivolol: A Selective Beta-Blocker for Heart Health

What is Nebivolol?

Nebivolol is a prescription medication belonging to the beta-blocker class of drugs, specifically categorized as a selective beta-1 adrenergic receptor antagonist. It is primarily used to treat high blood pressure (hypertension) and heart failure in adults. Unlike traditional beta-blockers, nebivolol has unique vasodilating properties that help relax blood vessels while blocking certain heart receptors.

Uses

High blood pressure (hypertension): Nebivolol is FDA-approved as a first-line treatment for hypertension, helping to lower blood pressure and reduce the risk of cardiovascular events such as heart attacks and strokes.

Heart failure with reduced ejection fraction: The medication is approved for treating stable, mild to moderate chronic heart failure in patients whose heart’s pumping ability has been compromised.

Cardiovascular risk reduction: By controlling blood pressure and improving heart function, nebivolol helps reduce the overall risk of heart disease complications in high-risk patients.

Submit Your Paper
GMJ_Submit_Banner

Post-myocardial infarction management: Healthcare providers may prescribe nebivolol as part of comprehensive treatment following a heart attack to improve long-term outcomes and prevent future cardiac events.

Angina prevention: Some doctors prescribe nebivolol off-label to help prevent chest pain episodes in patients with coronary artery disease, though this is not its primary indication.

How it works

Nebivolol works by selectively blocking beta-1 adrenergic receptors in the heart, which reduces heart rate and the force of heart contractions, thereby lowering blood pressure. Additionally, the drug stimulates the production of nitric oxide, a natural substance that causes blood vessels to relax and widen (vasodilation). This dual mechanism makes nebivolol particularly effective at improving blood flow while reducing the heart’s workload.

Side effects

Common side effects:

  • Headache
  • Fatigue or tiredness
  • Dizziness
  • Diarrhea
  • Nausea
  • Difficulty sleeping (insomnia)
  • Slow heart rate (bradycardia)
  • Shortness of breath

Serious side effects requiring immediate medical attention:

  • Severe allergic reactions (swelling of face, lips, throat)
  • Worsening heart failure symptoms (severe shortness of breath, rapid weight gain)
  • Extremely slow heart rate or irregular heartbeat
  • Severe dizziness or fainting
  • Signs of liver problems (yellowing of skin or eyes, dark urine)

Warnings and precautions

Contraindications: Patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, or severe liver impairment should not use nebivolol.

Gradual discontinuation required: Stopping nebivolol suddenly can cause dangerous rebound hypertension or worsen angina; the dose must be tapered gradually under medical supervision.

Diabetes monitoring: Beta-blockers can mask symptoms of low blood sugar, requiring more frequent glucose monitoring in diabetic patients.

Respiratory conditions: Use with caution in patients with asthma or chronic obstructive pulmonary disease, as beta-blockers may worsen breathing difficulties.

Pregnancy and breastfeeding: Nebivolol is classified as pregnancy category C; potential benefits must outweigh risks, and the drug may pass into breast milk.

Interactions

Calcium channel blockers (verapamil, diltiazem): Can cause excessive slowing of heart rate and dangerously low blood pressure when combined with nebivolol.

Digitalis medications: Concurrent use may increase the risk of bradycardia and heart conduction problems.

Insulin and diabetes medications: Nebivolol can mask hypoglycemia symptoms and may affect blood sugar control.

NSAIDs (ibuprofen, naproxen): These pain relievers can reduce the blood pressure-lowering effects of nebivolol.

Antiarrhythmic drugs (amiodarone, quinidine): May increase the risk of heart rhythm abnormalities when used together.

Anesthetics: Can enhance the blood pressure-lowering effects, requiring careful monitoring during surgery.

Clonidine: If both drugs are being discontinued, clonidine should be stopped first to avoid rebound hypertension.

CYP2D6 inhibitors (fluoxetine, paroxetine): These medications can increase nebivolol blood levels, potentially intensifying side effects.

Check interactions with the GMJ Interaction Checker

Dosage

For hypertension, the typical starting dose is 5 mg once daily, with or without food. Based on blood pressure response, the dose may be increased to 10 mg, 20 mg, or a maximum of 40 mg once daily at 1-2 week intervals. For heart failure, treatment usually begins with 1.25 mg once daily, gradually increased every 1-2 weeks as tolerated, up to a maximum of 10 mg daily. Elderly patients and those with kidney impairment may require lower starting doses. Dosage should always be determined and monitored by a healthcare provider based on individual patient factors and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Nebivolol." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/nebivolol/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Approves 47 New Pharmaceutical Manufacturing and Wholesale Dealer Licences in Latest MHRA Review

UK's MHRA has granted 47 new pharmaceutical manufacturing and wholesale dealer licences…

Eric Edwards, Pioneer of UK Kidney Transplantation, Dies

Eric Edwards, the pioneering British urologist who performed the first cadaver kidney…

UK Approves 47 New Pharmaceutical Manufacturing and Wholesale Dealer Licences in Latest MHRA Review

UK's MHRA has granted 47 new pharmaceutical manufacturing and wholesale dealer licences…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Propranolol

By
Prof. Giorgi Pkhakadze
02/06/2026

Atenolol

By
Prof. Giorgi Pkhakadze
02/06/2026

Metoprolol

By
Prof. Giorgi Pkhakadze
02/06/2026

Atenolol

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up